制药巨头美股盘前大涨50%！公司达成57亿美元许可交易

Core Viewpoint - The partnership between Swiss pharmaceutical giant Novartis and biotechnology company Monte Rosa is significant, with a total deal value of up to $5.7 billion for developing drugs to treat immune-mediated diseases [1] Group 1 - Novartis signed a licensing agreement with Monte Rosa worth up to $5.7 billion [1] - Monte Rosa will receive an upfront payment of $120 million as part of the agreement [1] - Following the announcement, Monte Rosa's stock surged by 50% in pre-market trading [1]